Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 06, 2023

SELL
$0.74 - $1.04 $222 - $312
-300 Reduced 37.5%
500 $0
Q2 2022

Jul 19, 2022

BUY
$0.87 - $2.03 $348 - $811
400 Added 100.0%
800 $1,000
Q4 2021

Jan 24, 2022

BUY
$2.34 - $5.31 $234 - $531
100 Added 33.33%
400 $1,000
Q3 2021

Oct 29, 2021

BUY
$1.89 - $8.53 $567 - $2,559
300 New
300 $1,000

About Corvus Pharmaceuticals, Inc.


  • Ticker CRVS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,553,500
  • Market Cap $401M
  • Description
  • Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...
More about CRVS
Track This Portfolio

Track Tci Wealth Advisors, Inc. Portfolio

Follow Tci Wealth Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.